Table 3. Summary of the IC50 concentrations presented from two breast cancer cell lines (MCF-7, MDA-MB-231) when treated with the indicated glycolytic inhibitors for 5 days under four different oxygen conditions (21% O2, 7% O2, 2% O2, and 0.5% O2).
| IC50 | MCF-7 | MDA-MB-231 | ||||||
|---|---|---|---|---|---|---|---|---|
| 21% O2 | 7% O2 | 2% O2 | 0.5% O2 | 21% O2 | 7% O2 | 2% O2 | 0.5% O2 | |
| STF31 (μM) | 1.284 | 2.277 | 1.445 | 1.613 | 1.243 | 1.803 | 2.367 | 2.162 |
| WZB117 (μM) | 2.3 | 16.419 | >30 | >30 | 4.079 | N/A | >30 | N/A |
| Phloretin (μM) | 90.016 | 295.224 | >300 | >300 | 69.644 | 289.107 | >300 | >300 |
| BP (μM) | 62.659 | >300 | N/A | >300 | 38.989 | >300 | N/A | >300 |
| 3PO (μM) | 1.34 | 3.759 | 3.481 | 3.673 | 1.486 | 11.232 | 8.574 | 12.9 |
| DCA (mM) | 13.043 | 18.91 | 19.558 | 12.569 | 23.3 | 38.904 | 36.967 | 31.079 |
| NHI1 (μM) | 61.778 | 80.026 | 150.111 | 111.495 | 93.628 | 190.059 | 227.572 | 174.091 |
| Oxamic acid(mM) | 10.4 | 39.368 | 47.089 | 49.478 | 6.944 | 60.431 | 66.192 | 73.993 |